On November 17-21, 2013, Manila (Philippines) welcomed the 8th International Conference for Radiopharmaceutical Therapy (8th ICRT) under the aegis of the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH).
Over 300 participants from 42 countries attended the conference. Main part of the conference schedule was dedicated to radionuclide therapy of the thyroid diseases, palliative therapy in the metastatic skeleton lesions, radio peptide therapy of neuroendocrine tumors, radiosynovectomy, molecular imaging in nuclear therapy, innovative therapy methods, history and development prospects of the nuclear medicine.
Results of the first clinical study for the new Russian radiopharmaceutical product Zoleren, 188Re (188Re-zoledronic acid) for palliative therapy in the metastatic skeleton lesions were presented during the conference (study is conducted in the department of radiosurgery targeted therapy of the Federal State Unitary Enterprise “Medical Radiological Research Center” of the Ministry of Healthcare of the Russian Federation (MRRC) (under doctor of medical science Krylov`s supervision). Presented results were based on the safety and efficiency study for administration of 35-55 MBq/kg to patients with descending malignant skeleton lesions and pain syndrome. According to study results, radiopharmaceutical product Zoleren, 188Re does not possess significant hematologic and other toxicity if administered activity is lower than 55 MBq/kg and quality of therapy was characterized as effective (Kochetova T. et al., 20131). Also on the conference were presented results of prognostic monitoring in assessment of safety and efficiency in clinical studies (Voloznev L. et al., 20132).
By conference results, researchers were honored with the highest award of the 8th ICRT for clinical study on RPP 188Re-zolendronic acid, and their work was recognized as the best science report on the 8th ICRT 2013.
Awarding Kochetova Tatyana (in the middle) and other conference participants:
8th International Conference for Radiopharmaceutical Therapy
Diploma of the 8th International Conference for Radiopharmaceutical Therapy
AO “Pharm-Sintez” congratulates all researchers with achieved success
Kochetova Tatyana Yurevna
Smolyarchuk Maxim Yaroslavovich
Krylov Valery Vasilevich
Voloznev Lev Vasilevich
Lunev Alexander Sergeevich
Petriev Vasily Mikhailovich
and wishes creative and scientific achievements in the new year!
1. Kochetova T., Smolyarchuk M., Krylov V., Voloznev L., Lunev A., Petriev V. 188Re-zoledronoca acid: first-in-man study // World Journal of Nuclear Medicine. – 2013. – V. 12(2). – P. 228-229.
2. Voloznev L.V., Lunev A.S., Klementyeva O.E., Korsunsky V.N. Pre-clinical dosimetry and prognosis of safety and effectiveness of radiopharmaceuticals 188Re-zoledronic acid //World Journal of Nuclear Medicine. – 2013. – V. 12(2). – P. 266.
2Voloznev L.V., Lunev A.S., Klementyeva O.E., Korsunsky V.N. Pre-clinical dosimetry and prognosis of safety and effectiveness of radiopharmaceuticals 188Re-zoledronic acid // World Journal of Nuclear Medicine. – 2013. – V. 12(2). – P. 266.